Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016

  • ID: 3743753
  • Drug Pipelines
  • 119 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Advaxis, Inc.
  • Aprea AB
  • Cellceutix Corporation
  • Eleos Inc.
  • ORCA Therapeutics B.V.
  • OSE Pharma SA
  • MORE
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016

Summary

‘Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016’, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

The report provides comprehensive information on the Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)
- The report reviews Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Advaxis, Inc.
  • Aprea AB
  • Cellceutix Corporation
  • Eleos Inc.
  • ORCA Therapeutics B.V.
  • OSE Pharma SA
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) Overview

Therapeutics Development

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Stage of Development

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Therapy Area

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Indication

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Companies

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Products under Development by Universities/Institutes

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Companies Involved in Therapeutics Development

Advaxis, Inc.

American Gene Technologies International Inc.

Aprea AB

Cellceutix Corporation

Critical Outcome Technologies Inc.

Eleos Inc.

ORCA Therapeutics B.V.

OSE Pharma SA

PCI Biotech Holding ASA

Quark Pharmaceuticals, Inc.

Stemline Therapeutics, Inc.

Shenzen SiBiono GeneTech Co., Ltd.

SK Biopharmaceuticals Co., Ltd.

Tara Immuno-Oncology Therapeutics LLC

Z53 Therapeutics, LLC

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Drug Profiles

Adxs-LmddA159 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APR-017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APR-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATRN-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenersen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contusugene ladenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-12PGJ3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KM-3174 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MHY-449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MJ-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MX-225 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

N-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Viruses to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPAL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate p53 for Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Cancer and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZMC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Dormant Projects

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Discontinued Products

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Featured News & Press Releases

Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers

Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer

Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002

Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients

Feb 22, 2016: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi for advanced non-small cell lung cancer

Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers

Feb 16, 2016: Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors

Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer

Feb 04, 2016: OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi Immunotherapy in Non-Small Cell Lung Cancer

Jan 22, 2016: Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Advaxis, Inc., H1 2016

Pipeline by American Gene Technologies International Inc., H1 2016

Pipeline by Aprea AB, H1 2016

Pipeline by Cellceutix Corporation, H1 2016

Pipeline by Critical Outcome Technologies Inc., H1 2016

Pipeline by Eleos Inc., H1 2016

Pipeline by ORCA Therapeutics B.V., H1 2016

Pipeline by OSE Pharma SA, H1 2016

Pipeline by PCI Biotech Holding ASA, H1 2016

Pipeline by Quark Pharmaceuticals, Inc., H1 2016

Pipeline by Stemline Therapeutics, Inc., H1 2016

Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016

Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016

Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016

Pipeline by Z53 Therapeutics, LLC, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Dormant Projects (Contd..3), H1 2016

Dormant Projects (Contd..4), H1 2016

Dormant Projects (Contd..5), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Advaxis, Inc.
  • Aprea AB
  • Cellceutix Corporation
  • Eleos Inc.
  • ORCA Therapeutics B.V.
  • OSE Pharma SA
  • MORE
Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) pipeline Target constitutes close to 29 molecules. Out of which approximately 24 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Cellular Tumor Antigen P53 – Pipeline Review, H1 2016, outlays comprehensive information on the Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 7, 7 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Advaxis, Inc.
American Gene Technologies International Inc.
Aprea AB
Cellceutix Corporation
Critical Outcome Technologies Inc.
Eleos Inc.
ORCA Therapeutics B.V.
OSE Pharma SA
PCI Biotech Holding ASA
Quark Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Shenzen SiBiono GeneTech Co., Ltd.
SK Biopharmaceuticals Co., Ltd.
Tara Immuno-Oncology Therapeutics LLC
Z53 Therapeutics, LLC
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll